Clinical Trials Logo

Osler Weber Rendu Disease clinical trials

View clinical trials related to Osler Weber Rendu Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04113187 Completed - Clinical trials for Hereditary Hemorrhagic Telangiectasia

Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients

EPERO
Start date: June 23, 2020
Phase: Phase 3
Study type: Interventional

Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of angiogenesis associated with disabling epistaxis. Management of these nose bleedings requires more effective treatment. Propranolol, a beta-blocker, is a potentially useful therapeutic considering its anti-angiogenic properties. Our objective is to explore the efficacy of propranolol, three months after its introduction, on the cumulative duration of epistaxis in HHT patients.